查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1300974

血栓和止血生物標誌物市場規模、份額和趨勢分析報告：按產品、按測試地點、按測試類型、按應用、按最終用途、按地區、細分市場預測，2023-2030 年

Thrombosis And Hemostasis Biomarkers Market Size, Share & Trends Analysis Report By Product (Analyzers, Reagents & Consumables), By Test Location, By Test Type, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

血栓和止血生物標誌物市場增長和趨勢

全球血栓和止血生物標誌物市場規模預計2023年至2030年復合年增長率為5.90%，2030年達到79.2億美元。

市場的快速增長歸因於胰腺癌等慢性病患病率的增加、人口老齡化的加劇、個性化藥物需求的增加以及技術進步等因素。

由於採用模式的變化和新技術的引入，血栓和止血生物標誌物行業近年來顯著增長。 市場上 POC 分析儀日益普及的趨勢是緊湊型分析儀的驅動力。 對小型和超小型設備的研究預計將繼續增加。 例如，2022年6月，Arnold Lining Ju博士宣布開發出一種微型設備，可以檢測血栓，可用於檢測心髒病發作的早期跡象。

深靜脈血栓 (DVT)、肺栓塞 (PE) 和胰腺癌等慢性疾病的流行預計將增加對血栓止血生物標誌物的需求，以檢測止血潛力。 慢性疾病往往會損害血管，導致形成血栓，限制血液流動，並可能導致中風和心髒病等嚴重的健康並發症。 例如，肺栓塞 (PE) 是一種嚴重的疾病，從腿部開始並傳播到肺部以阻止血液流動。

據美國肺臟協會稱，2023年1月，美國將有近90萬人發生肺栓塞，並且約33%的曾發生肺栓塞的人將在10年內再次發生肺栓塞的報導。 因此，病例的高患病率和高重複率導致對血栓和止血生物標誌物的需求增加。

此外，市場上的主要參與者正在專注於併購等各種形式的戰略舉措，以增強各自在血栓和止血生物標誌物行業的地位。 例如，2023 年 1 月，賽默飛世爾科技宣布與阿斯利康合作生產 Tagrisso 的血液和實體組織伴隨診斷測試。 預計這將推動血栓和止血生物標誌物行業的發展。 此外，2022 年 5 月，Quidel Corporation 以 60 億美元收購了 Ortho Clinical Diagnostics。 新公司名為 QuidelOrtho。 此次收購使 Quidel 能夠獲得 Ortho Clinical Diagnostics 的生物標誌物測試組合。

血栓止血生物標誌物市場報告亮點

  • 由於全球人口出血和凝血疾病的患病率不斷上升，試劑和耗材市場在 2022 年佔據了最大的銷售份額。
  • 臨床診斷將在 2022 年推動整個市場的發展，因為它們可以在處理大量樣本的同時診斷和識別凝血過程中的異常情況。
  • 由於可以監測抗凝功效的測試質量，凝血□後 (PT) 測試在 2022 年的銷售額中佔據最大份額。
  • 由於深靜脈血栓 (DVT) 的高患病率和高死亡風險，其在 2022 年的銷售額中所佔份額最大。
  • 診斷中心在 2022 年的銷售額中佔據最大份額，因為醫院越來越依賴診斷中心進行檢測，並且需要專用設備來提供更快的檢測結果。存在是不同的。
  • 由於血栓性疾病的高發病率和先進技術的普及，北美在 2022 年佔據了市場主導地位。
  • 主要市場參與者包括 BioMerieux SA、Abbott、Werfen、HORIBA Ltd.、Quidel Corporation、F. Hoffmann-La Roche Ltd.、Diazyme Laboratories, Inc.、Biomedica Diagnostics、Thermo Fisher Scientific, Inc.、Siemens Healthineers 等。

內容

第一章調查方法及範圍

  • 市場細分和範圍
  • 區域範圍
  • 估計/預測時間表
  • 目的
  • 調查方法
  • 信息獲取
  • 信息或數據分析
  • 市場形成和驗證
  • 型號詳細信息
  • 輔助信息列表
  • 縮寫列表

第 2 章執行摘要

第 3 章血栓止血生物標誌物市場變量、趨勢和範圍

  • 血栓和止血生物標誌物市場譜系展望
    • 母公司市場前景
    • 輔助市場
  • 市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
  • 血栓止血生物標誌物市場分析工具
    • 波特五力分析
    • 杵分析

第 4 章血栓和止血生物標誌物市場細分分析（按產品），2018-2030 年

  • 血栓和止血生物標誌物市場：產品變異分析
  • 按產品
    • 分析器
    • 試劑和消耗品

第 5 章血栓和止血生物標誌物市場 - 細分分析（按地點），2018-2030 年

  • 血栓和止血生物標誌物市場：測試地點的變化分析
  • 按檢查地點
    • 實驗室測試
    • 即時檢測

第 6 章血栓和止血生物標誌物市場 - 細分分析（按測試類型），2018-2030

  • 血栓和止血生物標誌物市場：測試類型的變異分析
  • 按測試類型
    • D-二聚體
    • 抗凝血□ III
    • 纖溶□原
    • 纖維蛋白/纖維蛋白原
    • 可溶性纖維蛋白
    • 選擇素
    • 因素 8
    • 點
    • 適合
    • 其他

第 7 章血栓和止血生物標記物市場細分分析（按應用），2018-2030

  • 血栓和止血生物標誌物市場：應用變化分析
  • 按用途
    • 深靜脈血栓形成 (Dvt)
    • 肺栓塞 (Pe)
    • 彌散性血管內凝血 (Dic)
    • 其他

第 8 章血栓和止血生物標誌物市場 - 細分分析，按最終用途，2018-2030 年

  • 血栓和止血生物標誌物市場：最終用途的變化分析
  • 按最終用途
    • 醫院和診所
    • 學術研究機構
    • 診斷中心
    • 其他

第 9 章血栓和止血生物標誌物市場：按地區、分產品、測試地點、測試類型、應用和最終用途進行估算和趨勢分析

  • 血栓市場：區域展望
  • 北美
    • 2018-2030 年北美血栓和止血生物標誌物市場估計和預測
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030 年歐洲血栓和止血生物標誌物市場估計和預測
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 丹麥
    • 瑞典
    • 挪威
    • 歐洲其他地區
  • 亞太地區
    • 2018-2030 年亞太地區血栓和止血生物標誌物市場估算和預測
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳大利亞
    • 泰國
    • 亞太地區其他地區
  • 拉丁美洲
    • 2018-2030 年拉丁美洲血栓和止血生物標誌物市場估計和預測
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲地區
  • MEA
    • 2018-2030 年 MEA 血栓和止血生物標誌物市場估算和預測
    • 南非
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 科威特
    • 其他中東/非洲

第 10 章競爭格局

  • 公司分類
  • 戰略規劃
    • 推出新產品
    • 合作夥伴關係
    • 獲取
    • 合作
    • 籌款
  • 2022 年主要參與者的市場份額分析
  • 公司簡介
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers
    • Abbott
    • BioMerieux SA
    • Werfen
    • HORIBA Ltd.
    • Quidel Corporation
    • Diazyme Laboratories, Inc.
    • Biomedica Diagnostics

第11章 結論

Product Code: GVR-4-68040-081-8

Thrombosis And Hemostasis Biomarkers Market Growth & Trends

The global thrombosis and hemostasis biomarkers market size is expected to reach USD 7.92 Billion by 2030, expanding at a CAGR of 5.90% from 2023 to 2030. The rapid growth of the market is attributable to factors such as the increasing prevalence of chronic diseases such as pancreatic cancer, the rise in the geriatric population, the growing demand for personalized medicines, and advancements in technology.

The thrombosis & hemostasis biomarkers industry has grown significantly in recent years, with changes in adoption patterns and the introduction of novel technologies. The increasing trend of adopting POC analyzers in the market is creating traction for small-sized analyzers. Increasing research on mini- and microdevices is anticipated to continue over the coming years. For instance, in June 2022, Dr. Arnold Lining Ju announced the development of a microdevice that can detect blood clots and can be used to detect early signs of a heart attack.

The prevalence of chronic diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), and pancreatic cancer is anticipated drive the need for thrombosis & hemostasis biomarkers to detect the probability of hemostasis. Chronic diseases have a tendency to damage blood vessels, leading to the formation of clots that can block blood flow and cause serious health complications, such as stroke & heart attack. For instance, pulmonary embolism (PE), is a serious medical condition that occurs in the legs and travels to the lung, obstructing blood flow.

As per American Lung Association, in January 2023, PE affected nearly 900,000 people in the U.S. and nearly 33% of the people affected by (DVT) or pulmonary embolism (PE) experience recurrence of PE in ten years. Therefore, high prevalence and significant repetition of cases will lead to an increase in the demand for thrombosis & hemostasis biomarkers.

Furthermore, key players operating in the market are focusing on different forms of strategic initiatives such as mergers and acquisitions to increase their respective position in the thrombosis & hemostasis biomarkers industry. For instance, in January 2023, Thermo Fisher Scientific, Inc., announced a partnership with AstraZeneca to manufacture a blood-based and solid tissue companion diagnostic test for Tagrisso. This was expected to propel the thrombosis and hemostasis biomarkers industry. Additionally, in May 2022, Quidel Corporation acquired Ortho Clinical Diagnostics for USD 6 billion. The new company was named QuidelOrtho. Through this acquisition, Quidel gained access to Ortho Clinical Diagnostics' biomarker tests portfolio.

Thrombosis And Hemostasis Biomarkers Market Report Highlights

  • Reagents and consumables segment of the market held the largest revenue share in 2022 and is attributable to the heightened prevalence of bleeding and coagulation disorders in the global population
  • Clinical laboratory tests led the overall market in 2022, owing to their ability to diagnose and identify abnormalities in the blood clotting process while processing a high volume of samples
  • Post-thrombin (PT) test held the largest revenue share in 2022, attributable to the test quality which allows monitoring the effectiveness of anticoagulant medications
  • Deep Vein Thrombosis (DVT) held the largest revenue share in 2022, owing to its high prevalence and the high mortality risk
  • Diagnostic centers held the largest revenue share in 2022, attributable to the growing reliance of hospitals on diagnostic centers for testing and the presence of specialized equipment to provide faster test results
  • North America dominated the market in 2022 which can be attributed to a significant prevalence of thrombosis and hemostasis disorders, along with access to advanced technology
  • A few of the key market playersinclude bioMerieux SA; Abbott; Werfen; HORIBA Ltd.; Quidel Corporation; F. Hoffmann-La Roche Ltd.; Diazyme Laboratories, Inc.; Biomedica Diagnostics; Thermo Fisher Scientific, Inc.; Siemens Healthineers.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Product Segment
      • 1.1.1.2 Test Location Segment
      • 1.1.1.3 Test Type Segment
      • 1.1.1.4 Application Segment
      • 1.1.1.5 End-Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Product And Test Location Segment Snapshot
  • 2.3 Test Type Segment Snapshot
  • 2.4 Application And End Use Segment Snapshot
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Thrombosis & Hemostasis Biomarkers Market Variables, Trends, And Scope

  • 3.1 Thrombosis & Hemostasis Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing Prevalence Of Chronic Diseases
      • 3.2.1.1.1 Incidence Data Of Pancreatic Cancer
      • 3.2.1.2 Growing Geriatric Population
      • 3.2.1.3 Increasing Demand For Personalized Medicine
      • 3.2.1.4 Advancements In Technology
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Cost Of Diagnostic Tests
      • 3.2.2.2 Complexity Of Thrombotic Events
  • 3.3 Thrombosis & Hemostasis Biomarkers Market Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Pestle Analysis

Chapter 4 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Product, 2018 - 2030 (USD Million)

  • 4.1 Thrombosis & Hemostasis Biomarkers Market: Product Movement Analysis
  • 4.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Product (USD Million)
    • 4.2.1 Analyzers
    • 4.2.2 Reagents & Consumables

Chapter 5 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Test Location, 2018 - 2030 (USD Million)

  • 5.1 Thrombosis & Hemostasis Biomarkers Market: Test Location Movement Analysis
  • 5.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Test Location (USD Million)
    • 5.2.1 Clinical Laboratory Tests
    • 5.2.2 Point-Of-Care Tests

Chapter 6 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Test Type, 2018 - 2030 (USD Million)

  • 6.1 Thrombosis & Hemostasis Biomarkers Market: Test Type Movement Analysis
  • 6.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Test Type (USD Million)
    • 6.2.1 D-Dimer
    • 6.2.2 Anti-Thrombin Iii
    • 6.2.3 Plasminogen
    • 6.2.4 Fibrin/Fibrinogen
    • 6.2.5 Soluble Fibrin
    • 6.2.6 Selectins
    • 6.2.7 Factor Viii
    • 6.2.8 Pt
    • 6.2.9 Aptt
    • 6.2.10 Others

Chapter 7 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 7.1 Thrombosis & Hemostasis Biomarkers Market: Application Movement Analysis
  • 7.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By Application (USD Million)
    • 7.2.1 Deep Vein Thrombosis (Dvt)
    • 7.2.2 Pulmonary Embolism (Pe)
    • 7.2.3 Disseminated Intravascular Coagulation (Dic)
    • 7.2.4 Others

Chapter 8 Thrombosis & Hemostasis Biomarkers Market - Segment Analysis, By End Use, 2018 - 2030 (USD Million)

  • 8.1 Thrombosis & Hemostasis Biomarkers Market: End-Use Movement Analysis
  • 8.2 Thrombosis & Hemostasis Biomarkers Market Estimates & Forecast, By End Use (USD Million)
    • 8.2.1 Hospitals & Clinics
    • 8.2.2 Academic & Research Institute
    • 8.2.3 Diagnostic Centers
    • 8.2.4 Others

Chapter 9 Thrombosis & Hemostasis Biomarkers Market: Regional Estimates And Trend Analysis, By Product, Test Location, Test Type, Application, & End-Use

  • 9.1 Thrombosis & Hemostasis Market: Regional Outlook
  • 9.2 North America
    • 9.2.1 North America Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 Key Country Dynamics
      • 9.2.2.2 Target Disease Prevalence
      • 9.2.2.3 U.S. Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.2.2.4 Competitive Scenario
      • 9.2.2.5 Regulatory Framework
      • 9.2.2.6 Reimbursement Scenario
    • 9.2.3 Canada
      • 9.2.3.1 Key Country Dynamics
      • 9.2.3.2 Target Disease Prevalence
      • 9.2.3.3 Canada Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.2.3.4 Competitive Scenario
      • 9.2.3.5 Regulatory Framework
      • 9.2.3.6 Reimbursement Scenario
  • 9.3 Europe
    • 9.3.1 Europe Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 Uk
      • 9.3.2.1 Key Country Dynamics
      • 9.3.2.2 Target Disease Prevalence
      • 9.3.2.3 Uk Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.2.4 Competitive Scenario
      • 9.3.2.5 Regulatory Framework
      • 9.3.2.6 Reimbursement Scenario
    • 9.3.3 Germany
      • 9.3.3.1 Key Country Dynamics
      • 9.3.3.2 Target Disease Prevalence
      • 9.3.3.3 Germany Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.3.4 Competitive Scenario
      • 9.3.3.5 Regulatory Framework
      • 9.3.3.6 Reimbursement Scenario
    • 9.3.4 France
      • 9.3.4.1 Key Country Dynamics
      • 9.3.4.2 Target Disease Prevalence
      • 9.3.4.3 France Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.4.4 Competitive Scenario
      • 9.3.4.5 Regulatory Framework
      • 9.3.4.6 Reimbursement Scenario
    • 9.3.5 Spain
      • 9.3.5.1 Key Country Dynamics
      • 9.3.5.2 Target Disease Prevalence
      • 9.3.5.3 Spain Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.5.4 Competitive Scenario
      • 9.3.5.5 Regulatory Framework
      • 9.3.5.6 Reimbursement Scenario
    • 9.3.6 Italy
      • 9.3.6.1 Key Country Dynamics
      • 9.3.6.2 Target Disease Prevalence
      • 9.3.6.3 Italy Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.6.4 Competitive Scenario
      • 9.3.6.5 Regulatory Framework
      • 9.3.6.6 Reimbursement Scenario
    • 9.3.7 Denmark
      • 9.3.7.1 Key Country Dynamics
      • 9.3.7.2 Target Disease Prevalence
      • 9.3.7.3 Denmark Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.7.4 Competitive Scenario
      • 9.3.7.5 Regulatory Framework
      • 9.3.7.6 Reimbursement Scenario
    • 9.3.8 Sweden
      • 9.3.8.1 Key Country Dynamics
      • 9.3.8.2 Target Disease Prevalence
      • 9.3.8.3 Sweden Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.8.4 Competitive Scenario
      • 9.3.8.5 Regulatory Framework
      • 9.3.8.6 Reimbursement Scenario
    • 9.3.9 Norway
      • 9.3.9.1 Key Country Dynamics
      • 9.3.9.2 Target Disease Prevalence
      • 9.3.9.3 Norway Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.3.9.4 Competitive Scenario
      • 9.3.9.5 Regulatory Framework
      • 9.3.9.6 Reimbursement Scenario
    • 9.3.10 Rest Of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Death Rate In Japan
      • 9.4.2.3 Target Disease Prevalence
      • 9.4.2.4 Japan Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.2.5 Competitive Scenario
      • 9.4.2.6 Regulatory Framework
      • 9.4.2.7 Reimbursement Scenario
    • 9.4.3 China
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 Target Disease Prevalence
      • 9.4.3.3 China Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.3.4 Competitive Scenario
      • 9.4.3.5 Regulatory Framework
      • 9.4.3.6 Reimbursement Scenario
    • 9.4.4 India
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 Target Disease Prevalence
      • 9.4.4.3 India Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.4.4 Competitive Scenario'
      • 9.4.4.5 Regulatory Framework
      • 9.4.4.6 Reimbursement Scenario
    • 9.4.5 South Korea
      • 9.4.5.1 Key Country Dynamics
      • 9.4.5.2 Target Disease Prevalence
      • 9.4.5.3 South Korea Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.5.4 Competitive Scenario
      • 9.4.5.5 Regulatory Framework
      • 9.4.5.6 Reimbursement Scenario
    • 9.4.6 Australia
      • 9.4.6.1 Key Country Dynamics
      • 9.4.6.2 Target Disease Prevalence
      • 9.4.6.3 Australia Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.6.4 Competitive Scenario
      • 9.4.6.5 Regulatory Framework
      • 9.4.6.6 Reimbursement Scenario
    • 9.4.7 Thailand
      • 9.4.7.1 Key Country Dynamics
      • 9.4.7.2 Target Disease Prevalence
      • 9.4.7.3 Thailand Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.4.7.4 Competitive Scenario
      • 9.4.7.5 Regulatory Framework
      • 9.4.7.6 Reimbursement Scenario
    • 9.4.8 Rest Of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Latin America Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Brazil Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.5.2.3 Target Disease Prevalence
      • 9.5.2.4 Competitive Scenario
      • 9.5.2.5 Regulatory Framework
      • 9.5.2.6 Reimbursement Scenario
    • 9.5.3 Mexico
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Target Disease Prevalence
      • 9.5.3.3 Mexico Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.5.3.4 Competitive Scenario
      • 9.5.3.5 Regulatory Framework
      • 9.5.3.6 Reimbursement Scenario
    • 9.5.4 Argentina
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Target Disease Prevalence
      • 9.5.4.3 Argentina Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.5.4.4 Competitive Scenario
      • 9.5.4.5 Regulatory Framework
      • 9.5.4.6 Reimbursement Scenario
    • 9.5.5 Rest Of Latin America
  • 9.6 MEA
    • 9.6.1 MEA Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 Key Country Dynamics
      • 9.6.2.2 Target Disease Prevalence
      • 9.6.2.3 South Africa Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.2.4 Competitive Scenario
      • 9.6.2.5 Regulatory Framework
      • 9.6.2.6 Reimbursement Scenario
    • 9.6.3 Saudi Arabia
      • 9.6.3.1 Key Country Dynamics
      • 9.6.3.2 Target Disease Prevalence
      • 9.6.3.3 Saudi Arabia Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.3.4 Competitive Scenario
      • 9.6.3.5 Regulatory Framework
      • 9.6.3.6 Reimbursement Scenario
    • 9.6.4 UAE
      • 9.6.4.1 Key Country Dynamics
      • 9.6.4.2 Target Disease Prevalence
      • 9.6.4.3 Uae Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.4.4 Competitive Scenario
      • 9.6.4.5 Regulatory Framework
      • 9.6.4.6 Reimbursement Scenario
    • 9.6.5 Kuwait
      • 9.6.5.1 Key Country Dynamics
      • 9.6.5.2 Target Disease Prevalence
      • 9.6.5.3 Kuwait Thrombosis & Hemostasis Biomarkers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 9.6.5.4 Competitive Scenario
      • 9.6.5.5 Regulatory Framework
      • 9.6.5.6 Reimbursement Scenario
    • 9.6.6 Rest Of Mea

Chapter 10 Competitive Landscape

  • 10.1 Company Categorization
  • 10.2 Strategy Mapping
    • 10.2.1 New Product Launch
    • 10.2.2 Partnerships
    • 10.2.3 Acquisition
    • 10.2.4 Collaboration
    • 10.2.5 Funding
  • 10.3 Key Company Market Share Analysis, 2022
  • 10.4 Company Profiles
    • 10.4.1 Thermo Fisher Scientific, Inc.
      • 10.4.1.1 Company Overview
      • 10.4.1.2 Financial Performance
      • 10.4.1.3 Product Benchmarking
      • 10.4.1.4 Strategic Initiatives
    • 10.4.2 F. Hoffmann-La Roche Ltd.
      • 10.4.2.1 Company Overview
      • 10.4.2.2 Financial Performance
      • 10.4.2.3 Product Benchmarking
      • 10.4.2.4 Strategic Initiatives
    • 10.4.3 Siemens Healthineers
      • 10.4.3.1 Company Overview
      • 10.4.3.2 Financial Performance
      • 10.4.3.3 Product Benchmarking
      • 10.4.3.4 Strategic Initiatives
    • 10.4.4 Abbott
      • 10.4.4.1 Company Overview
      • 10.4.4.2 Financial Performance
      • 10.4.4.3 Product Benchmarking
      • 10.4.4.4 Strategic Initiatives
    • 10.4.5 BioMerieux SA
      • 10.4.5.1 Company Overview
      • 10.4.5.2 Financial Performance
      • 10.4.5.3 Product Benchmarking
      • 10.4.5.4 Strategic Initiative
    • 10.4.6 Werfen
      • 10.4.6.1 Company Overview
      • 10.4.6.2 Financial Performance
      • 10.4.6.3 Product Benchmarking
      • 10.4.6.4 Strategic Initiatives
    • 10.4.7 HORIBA Ltd.
      • 10.4.7.1 Company Overview
      • 10.4.7.2 Financial Performance
      • 10.4.7.3 Product Benchmarking
      • 10.4.7.4 Strategic Initiatives
    • 10.4.8 Quidel Corporation
      • 10.4.8.1 Company Overview
      • 10.4.8.2 Financial Performance
      • 10.4.8.3 Product Benchmarking
      • 10.4.8.4 Strategic Initiatives
    • 10.4.9 Diazyme Laboratories, Inc.
      • 10.4.9.1 Company Overview
      • 10.4.9.2 Financial Performance
      • 10.4.9.3 Product Benchmarking
      • 10.4.9.4 Strategic Initiatives
    • 10.4.10 Biomedica Diagnostics
      • 10.4.10.1 Company Overview
      • 10.4.10.2 Financial Performance
      • 10.4.10.3 Product Benchmarking
      • 10.4.10.4 Strategic Initiatives

Chapter 11 Conclusion

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 5 Global thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 6 Global thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 7 Global thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 Global thrombosis & hemostasis biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 9 North America thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 10 North America thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 11 North America thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 12 North America thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 13 North America thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 14 North America thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 15 U.S. thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 16 U.S. thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 17 U.S. thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 18 U.S. thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 19 U.S. thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 Canada thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 21 Canada thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 22 Canada thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 23 Canada thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 24 Canada thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 25 Europe thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 26 Europe thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 27 Europe thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 28 Europe thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 29 Europe thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 30 Europe thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 31 Germany thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 32 Germany thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 33 Germany thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 34 Germany thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 35 Germany thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 36 UK thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 37 UK thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 38 UK thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 39 UK thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 40 UK thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 France thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 42 France thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 43 France thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 44 France thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 45 France thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Italy thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 47 Italy thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 48 Italy thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Italy thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 50 Italy thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 51 Spain thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 52 Spain thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 53 Spain thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 54 Spain thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 55 Spain thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Denmark thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 57 Denmark thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 58 Denmark thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 59 Denmark thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 60 Denmark thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 Sweden thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 62 Sweden thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 63 Sweden thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 64 Sweden thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 65 Sweden thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 66 Norway thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 67 Norway thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 68 Norway thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 69 Norway thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 70 Norway thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 77 China thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 78 China thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 79 China thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 80 China thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 81 China thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 82 Japan thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 83 Japan thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 84 Japan thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 85 Japan thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 86 Japan thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 87 India thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 88 India thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 89 India thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 90 India thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 91 India thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 92 South Korea thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 93 South Korea thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 94 South Korea thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 95 South Korea thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 96 South Korea thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 97 Australia thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 98 Australia thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 99 Australia thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 100 Australia thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 101 Australia thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 102 Thailand thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 103 Thailand thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 104 Thailand thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 105 Thailand thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 106 Thailand thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 107 Latin America thrombosis & hemostasis biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 108 Latin America thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 109 Latin America thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 110 Latin America thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 111 Latin America thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 112 Latin America thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 113 Brazil thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 114 Brazil thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 115 Brazil thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 116 Brazil thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 117 Brazil thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 118 Mexico thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 119 Mexico thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 120 Mexico thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 121 Mexico thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 122 Mexico thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 123 Argentina thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 124 Argentina thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 125 Argentina thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 126 Argentina thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 127 Argentina thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 128 Middle East & Africa thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 129 Middle East & Africa thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 130 Middle East & Africa thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 131 Middle East & Africa thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 132 Middle East & Africa thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 133 South Africa thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 134 South Africa thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 135 South Africa thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 136 South Africa thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 137 South Africa thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 138 Saudi Arabia thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 142 Saudi Arabia thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 143 UAE thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 144 UAE thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 145 UAE thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 146 UAE thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 147 UAE thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 148 Kuwait thrombosis & hemostasis biomarkers market, by product, 2018 - 2030 (USD Million)
  • Table 149 Kuwait thrombosis & hemostasis biomarkers market, by test location, 2018 - 2030 (USD Million)
  • Table 150 Kuwait thrombosis & hemostasis biomarkers market, by test type, 2018 - 2030 (USD Million)
  • Table 151 Kuwait thrombosis & hemostasis biomarkers market, by applications, 2018 - 2030 (USD Million)
  • Table 152 Kuwait thrombosis & hemostasis biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Thrombosis & hemostasis biomarkers market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Product and test location segment snapshot
  • Fig. 11 Test type segment snapshot
  • Fig. 12 Application and end-use segment snapshot
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 IVD market value, 2022 (USD Million)
  • Fig. 15 Market dynamics
  • Fig. 16 Incidence of global pancreatic cancer, 2017 - 2021
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTLE analysis
  • Fig. 19 Thrombosis & hemostasis biomarkers market: Product outlook and key takeaways
  • Fig. 20 Thrombosis & hemostasis biomarkers market: Product movement analysis
  • Fig. 21 Analyzers Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Reagents & consumables market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Thrombosis & hemostasis biomarkers market: Test location outlook and key takeaways
  • Fig. 24 Thrombosis & hemostasis biomarkers market: Test location movement analysis
  • Fig. 25 Clinical laboratory tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Point-of-care tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Thrombosis & hemostasis biomarkers market: Test type outlook and key takeaways
  • Fig. 28 Thrombosis & hemostasis biomarkers market: Test type movement analysis
  • Fig. 29 D- dimer test market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Anti-thrombin III market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Plasminogen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Fibrin/Fibrinogen Market Estimates and Forecast, 2018-2030, USD Million
  • Fig. 33 Soluble fibrin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Selectins Market Estimates and Forecast, 2018-2030, USD Million
  • Fig. 35 Factor VIII market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 PT market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 APTT Market Estimates and Forecast, 2018-2030, USD Million
  • Fig. 38 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Thrombosis & hemostasis biomarkers market: Application outlook and key takeaways
  • Fig. 40 Thrombosis & hemostasis biomarkers market: Application movement analysis
  • Fig. 41 Deep Vein Thrombosis (DVT) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Pulmonary Embolism (PE) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Disseminated Intravascular Coagulation (DIC) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Thrombosis & hemostasis biomarkers market: End-use outlook and key takeaways
  • Fig. 46 Thrombosis & hemostasis biomarkers market: End-use movement analysis
  • Fig. 47 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Academic & research institute market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Thrombosis & hemostasis biomarkers market revenue, by region, 2022 & 2030, (USD Million)
  • Fig. 52 Regional marketplace: Key takeaways
  • Fig. 53 Regional marketplace: Key takeaways
  • Fig. 54 North America thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 U.S. thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Canada thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Europe thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 UK thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Germany thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 France thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Spain thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Italy thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Denmark thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Sweden thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Norway thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Rest of Europe thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD, Million)
  • Fig. 77 Asia Pacific thrombosis & hemostasis biomarkers market estimates and forecast, 2018 - 2030, (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Japan thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 China thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 India thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 South Korea thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Korea reimbursement scenario
  • Fig. 87 Key country dynamics
  • Fig. 88 Australia thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Thailand thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Rest of Asia Pacific thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Latin America thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Brazil thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Mexico thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Argentina thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Rest of Latin America thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 MEA thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 South Africa thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Saudi Arabia thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 UAE thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 107 Key country dynamics
  • Fig. 108 Kuwait thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Rest of MEA thrombosis & hemostasis biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key company categorization
  • Fig. 111 Company categorization
  • Fig. 112 Company market share analysis, 2022
  • Fig. 113 North America - company market share analysis, 2022
  • Fig. 114 Europe- company market share analysis, 2022
  • Fig. 115 Asia Pacific- company market share analysis, 2022
  • Fig. 116 Latin America- company market share analysis, 2022
  • Fig. 117 MEA- company market share analysis, 2022
  • Fig. 118 Strategic framework